Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease | Zendy

Erland Erdmann | Zendy; B Charbonnel | Zendy; Robert A. Wilcox | Zendy; Allan M. Skene | Zendy; Massimo MassiBenedetti | Zendy; John Yates | Zendy; Meng H. Tan | Zendy; Robert G. Spanheimer | Zendy; Eberhard Standl | Zendy; John Dormandy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease

Author(s) -

Erland Erdmann,

B Charbonnel,

Robert A. Wilcox,

Allan M. Skene,

Massimo MassiBenedetti,

John Yates,

Meng H. Tan,

Robert G. Spanheimer,

Eberhard Standl,

John Dormandy

Publication year - 2007

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc07-0717

Subject(s) - pioglitazone , medicine , heart failure , placebo , cardiology , clinical endpoint , diabetes mellitus , type 2 diabetes , heart disease , adverse effect , clinical trial , endocrinology , pathology , alternative medicine

PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) enrolled patients with type 2 diabetes and preexisting cardiovascular disease. These patients were at high risk for heart failure, so any therapeutic benefit could potentially be offset by risk of associated heart failure mortality. We analyzed the heart failure cases to assess the effects of treatment on morbidity and mortality after reports of serious heart failure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research